|
HEARTWARE LIMITED ASX: HTW - Introduction to Heartware - Mr Howard Leibman, Director of Corporate development
Sydney, May 29, 2006 (ABN Newswire) - HEARTWARE LIMITED (ASX: HTW) - Introduction to Heartware - Mr Howard Leibman, Director of Corporate development; Boardroomradio is pleased to announce that HEARTWARE LIMITED (ASX: HTW) has published an audio file. The following presentation "HTW - Introduction to Heartware" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast. The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider. Broadcaster: HEARTWARE LIMITED (ASX: HTW) Broadcast Title: HTW - Introduction to Heartware Broadcast Type: Audio stream View the Audio stream for HEARTWARE LIMITED (ASX: HTW) by clicking on the following links. Display in Windows Media Player http://www.boardroomradio.com/event/HTW/641/11244/wmp/221.242.254.150/wsl.wmp? or: Display in MP3 Player or Transfer to Portable Podcast Device http://www.boardroomradio.com/event/HTW/641/11244/mp3/221.242.254.150/wsl.mp3? Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.
About HEARTWARE LIMITED
HeartWare is developing a family of proprietary circulatory assist devices to treat patients with congestive heart failure. HeartWare's lead device, the HVAD, commenced human clinical trials in March 2006. First sales are anticipated in late 2007. With a volume of 45cc, the HVAD is the smallest "3rd generation" pump and the only full output device implantable within the pericardial space.
In parallel with the HVAD clinical development, HeartWare is pursuing its MVAD program, aimed at developing a family of miniaturized cardiac assist devices, implantable by minimally invasive surgical techniques. The current MVAD prototype, approximately one tenth the volume of the HVAD, commenced animal studies in August 2005.
HeartWare listed on the Australian Stock Exchange (ASX: HTW) on 31 January 2005 after successfully raising A$32.4 million (US$24.95 million). HeartWare's Head Office is located in Sydney, Australia.
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
|
